In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: Immunomodulation and attenuation of murine colitis

British Journal of Nutrition

Volumn 100, Issue 3, 2008, Pages 530-541

  Fitzpatrick, Leo R ^a   Small, Jeffrey ^a   Hoerr, Robert A ^b   Bostwick, Eileen F ^b   Maines, Lynn ^c   Koltun, Walter A ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Bio Balance   (United States)

^c APOGEE BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Cytokines; Escherichia coli strain M 17; Nuclear factor B; p65; Probiotics

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METRONIDAZOLE; MYELOPEROXIDASE; PROBIOTIC AGENT; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL LINE; COLITIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ESCHERICHIA COLI; HISTOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN BINDING; SCORING SYSTEM; SIGNAL TRANSDUCTION; STIMULATION;

ANIMALS; ANTI-INFECTIVE AGENTS; CELL LINE; COLITIS; COLON; ESCHERICHIA COLI; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUCIFERASES; MACROPHAGES; MALE; METRONIDAZOLE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PEROXIDASE; PROBIOTICS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI; MURINAE; MUS;

EID: 49649091620     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508930373     Document Type: Article

References (52)

1. Fedorak RN & Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Disi 10, 286-299.
2. Shanahan F (2005) Physiological basis for novel drug therapies to treat the inflammatory bowel diseases: I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 288, G417-G421.
3. Strober W (1998) Interactions between epithelial cells and immune cells in the intestines. Ann N Y Acad Sci 859, 37-45.
4. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C & Chang EB (2004) Probiotics inhibit nuclear factor-κB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127, 1474-1487.
5. Baeuerle PA & Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12, 141-179.
6. Baldwin AS (1996) The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 14, 649-683.
7. Tak PP & Firestein GS (2001) NF-κB: A key role in inflammatory disease. J Clin Invest 107, 7-11.
8. Jobin C & Sartor RB (2000) NF-κB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 6 206-213.
9. Jobin C & Sartor RB (2000) The IκB/NF-κB system. A key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 278, C451-C462.
10. Lee JI & Burckart GJ (1998) Nuclear factor-κB: Important transcription factor and therapeutic target. J Clin Pharmacol 38, 981-993.
11. Schottelius AJG & Baldwin AS (1999) A role for transcription factor NF-κB in intestinal inflammation. Int J Colorectal Dis 14, 18-28.
12. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C & Madsen K (2004) DNA from probiotic bacteria modulates routine and human epithelial and immune function. Gastroenterology 126, 1358-1373.
13. Osman N, Adawi D, Ahrne S, Jeppsson B & Molin G (2004) Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dis Dis Sci 49, 320-327.
14. Arakai Y, Andoh A, Takizawa J, Takizawa W & Fujiyama Y (2004) Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med 13, 577-580.
15. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eyesselein VE & Buchler MW (2000) Characterization of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion 62, 240-248.
16. Strober W, Fuss LJ & Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20, 495-549.
17. Kitajima S, Takuma S & Morimoto M (1999) Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 48, 137-143.
18. Spiik AK, Ridderstad A, Axelsson LG, Midtyedt T, Bkork L & Pattersen S (2002) Abrogated lymphocyte infiltration and lowered CD14 in dextran sulfate induced colitis in mice treated with p65 oligonucleotides. Int J Colorectal Dis 17, 223-232.
19. Murano M, Maemura K, Hirata I, Toshina Y, Nishiwaka T, Hammamoto N, Sasaki S, Saitoh O & Katsu K (2000) Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 120, 51-58.
20. Adler SN, Jacob H & Eliakim R (2003) The probiotic agent Ecoli strain ATCC20226 has a healing effect on proximal inflammation in the small bowel (Abstract). Gastroenterology 120, A-527.
21. Bogomolov BP & Genina GS (1979) KinumqecK- (Clinical evaluation of colibacterin in the treatment of patients with dysentery and its role in restoration of biocenosis). Ter Arkh 51, 94-98.
22. Kurnosova NA, Zatsepin IuK & Feklisova LV (1979) (Biological preparations in the overall therapy of children convalescing after dysentery). Zh Mikrobiol Epidemiol Immunobiol, April, 21-25.
23. Kokesova A, Frolova L, Kvberka M, Sokol D, Rossmann P, Bartova J & Tsaskalova-Hogenova H (2006) Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 51, 478-484.
24. Rath HC, Schulz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J & Sartor RB (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69, 2277-2285.
25. Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA & Sedergan DJ (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 38, 1722-1734.
26. Fitzpatrick LR, Wang J & Le T (2000) In vitro and in vivo effects of gliotoxin, a fungal metabolite: Efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 45, 2327-2336.
27. Krieglstein CF, Cerwinka WH, Laroux FS, Grisham MB, Schurmann G, Bruwer M & Granger DN (2001) Role of appendix and spleen in experimental colitis. J Surg Res 101, 166-175.
28. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB & Lund PK (2001) Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120, 925-937.
29. Fitzpatrick LR, Wang J & Le T (2002) Gliotoxin, an inhibitor of nuclear factor-κB, attenuates peptidoglycan-polysaccharide-induced colitis in rats. Inflamm Bowel Dis 8, 159-167.
30. Bouma G & Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3, 521-533.
31. Neurath MF, Becker C & Barbulescu K (1998) Role of NF-κB in immune and inflammatory responses in the gut. Gut 43, 856-860.
32. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knueshel R, Bauerle PA, Schlomerich J & Gross V (1998) Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357-369.
33. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H & Ziegler R (1999) Cell specific effects of glucocorticoid treatment on the NF-κB p65/IκBα system in patients with Crohn's disease. Gut 445, 693-704.
34. Nikolaus S, Fo1sch UR & Schreiber S (2000) Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 47, 71-82.
35. Yan FY & Polk DB (1999) Aminosalicylic acid inhibits IκB kinase ot phosphorylation of IκBα in mouse intestinal epithelial cells. J Biol Chem 274, 36631-36636.
36. Hauf N & Chakraborty T (2003) Suppression of NF-κB activation and proinflammatory cytokine secretion by Shiga toxin-producing Escheiichia coli. J Immunol 170, 2074-2082.
37. Selvaraj SK & Prasadarao NV (2005) Escherichia coli K1 inhibits proinflammatory cytokine induction in monocytes by preventing NF-κB activation. J Leukoc Biol 78, 544-554.
38. O'Hara AM, O'Regan P, Fanning A, O'Mahony C, Macsharry J, Lyons A, Bienenstock J, O'Mahony L & Shanahan F (2006) Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118, 202-215.
39. Bai AP, Ouyang Q, Xiao XR & Li SF (2006) Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract 60, 284-288.
40. Grabig A, Paclik D, Gurzy C, et al. (2006) Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 74, 4075-4082.
41. Wehkamp J, Harder J, Wehkamp K, et al. (2004) NF-κB- and AP-1-mediated induction of human defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917; a novel effect of a probiotic bacterium. Infect Immun 72, 5750-5758.
42. Ruiz PA, Hoffman M, Szcesnys S, Blaut M & Haller D (2005) Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats. Immunology 115, 441-450.
43. Maresca M, Miller D, Quitaed S, Dean P & Kenny B (2005) Enteropathogenic Escherichia coli (EPEC) effector-mediated suppression of antimicrobial nitric oxide production in a small intestinal epithelia] model system. Cell Microbiol 7, 1749-1762.
44. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N & Heyman M (2004) Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53 821-828.
45. Blichfeldt P, Blomhoff JP, Myhre E & Gjone E (1978) Metronidazole in Crohn's disease. Scand J Gastroenterology 13, 123-127.
46. Ursing B & Kamme G (1975) Metronidazole for Crohn's disease. Lancet 1, 775-777.
47. Lahat G, Halperin D, Barazovsky E, Shalit I, Rabau M, Klausner J & Fabian I (2007) Immodulatory effects of ciprolloxacin in TNBS-induced colitis in mice. Inflamm Bowel Dis 13, 557-565.
48. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R & Kerremans R (1995) Controlled trial of metronidazole treatment for the prevention of Crohn's recurrence after ileal resection. Gastroenterology 108, 1617-1621.
49. Hans W, Scholmerich J, Gross V & Falk W (2000) The role of resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 12, 267-273.
50. Gaudio E, Taddei G, Vetuschi A, Sferrea R, Frieri G, Ricciardi G & Caprilli R (1999) Dextran sulfate sodium (DSS) colitis in rats. Clinical, structural and ultrastructural aspects. Dig Dis Sci 44, 1458-1475.
51. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeir F, Gottl C, Danger N, Grunwald N, Scholmerich J & Rath HC (2004) Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 11, 372-378.
52. Di Giacinto C, Marinaro, M, Sanchez M, Strober W & Boirvant M (2005) Probiotics ameliorate recurrent Th-1 mediated murine colitis by inducing IL-10 and IL-10 dependent TGF-β bearing regulatory cells. J Immunol 174, 3237-3246.